XENT Profile
Intersect ENT, Inc. (XENT) is a medical technology company that develops products for the treatment of ear, nose, and throat conditions. Its main product is the PROPEL family of products, which are drug-eluting implants designed to improve surgical outcomes for patients with chronic sinusitis. PROPEL implants are designed to release a steroid drug over time, reducing inflammation and promoting healing.
In addition to the PROPEL product line, Intersect ENT also offers the SINUVA implant, a non-surgical treatment for nasal polyps that can be administered in the doctor's office.
Intersect ENT was founded in 2003 and is headquartered in Menlo Park, California. The company went public in 2014 and is traded on the NASDAQ exchange under the ticker symbol XENT.
|
